SCHEMBL266507

SCHEMBL266507

COC(=O)c1cc(N2CCCCC2)ccc1NC(=O)c1cccc(CCl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.49
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
SMN1; SMN2 Q16637 6/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 3/20 0.48
HPGD P15428 1/20 0.48
MAPT P10636 5/20 0.47
LMNA P02545 3/20 0.47
QSOX1 O00391 1/20 0.47
PKM P14618 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SERPINE1 P05121 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.45
GFER P55789 1/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267854 0.91 NPC1 (0.48) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL268159 0.85 F10 (0.54) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL266433 0.82 HTR6 (0.47) HTR6NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL268374 0.82 ALDH1A1 (0.55) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL267931 0.81 HPGD (0.57) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL267492 0.81 MET (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL266632 0.80 SMN1; SMN2 (0.54) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL266398 0.80 AKR1C2 (0.54) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL46907 0.79 F10 (0.51) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL266810 0.76 KDM4E (0.54) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 HTR6 2560/4885NPC1 102/4885RAB9A 883/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 HTR6 2555/4885NPC1 115/4885RAB9A 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.